

Klaus F Rabe

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5755443/publications.pdf>

Version: 2024-02-01

622
papers

56,117
citations

1530

106
h-index

1456

220
g-index

693
all docs

693
docs citations

693
times ranked

37566
citing authors

#	ARTICLE	IF	CITATIONS
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2007, 176, 532-555.	2.5	5,801
2	Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 8-160.	2.7	3,827
3	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. New England Journal of Medicine, 2018, 378, 2486-2496.	13.9	1,253
4	Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. European Respiratory Journal, 2003, 22, 1-1.	3.1	948
5	Chronic Obstructive Pulmonary Disease Phenotypes. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 598-604.	2.5	898
6	Clinical management of asthma in 1999: the Asthma Insights and Reality in Europe (AIRE) study. European Respiratory Journal, 2000, 16, 802-807.	3.1	858
7	Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet, The, 2004, 364, 613-620.	6.3	844
8	Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. New England Journal of Medicine, 2018, 378, 2475-2485.	13.9	816
9	Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. Journal of Allergy and Clinical Immunology, 2004, 114, 40-47.	1.5	789
10	Oral Glucocorticoidâ€™Sparing Effect of Benralizumab in Severe Asthma. New England Journal of Medicine, 2017, 376, 2448-2458.	13.9	779
11	Outcomes for COPD pharmacological trials: from lung function to biomarkers. European Respiratory Journal, 2008, 31, 416-469.	3.1	732
12	The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma. European Respiratory Journal, 2003, 22, 470-477.	3.1	722
13	Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet, The, 2009, 374, 685-694.	6.3	717
14	Chronic obstructive pulmonary disease. Lancet, The, 2017, 389, 1931-1940.	6.3	712
15	Management of non-small-cell lung cancer: recent developments. Lancet, The, 2013, 382, 709-719.	6.3	658
16	Tiotropium versus Salmeterol for the Prevention of Exacerbations of COPD. New England Journal of Medicine, 2011, 364, 1093-1103.	13.9	603
17	Precision Diagnosis and Treatment for Advanced Nonâ€™Small-Cell Lung Cancer. New England Journal of Medicine, 2017, 377, 849-861.	13.9	578
18	Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet, The, 2009, 374, 695-703.	6.3	557

#	ARTICLE	IF	CITATIONS
19	Complex chronic comorbidities of COPD. <i>European Respiratory Journal</i> , 2008, 31, 204-212.	3.1	538
20	From COPD to chronic systemic inflammatory syndrome?. <i>Lancet, The</i> , 2007, 370, 797-799.	6.3	522
21	Mediastinoscopy vs Endosonography for Mediastinal Nodal Staging of Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 2245.	3.8	517
22	The Asthmaâ€œCOPD Overlap Syndrome. <i>New England Journal of Medicine</i> , 2015, 373, 1241-1249.	13.9	489
23	Allergic Rhinitis and its Impact on Asthma (ARIA): Achievements in 10 years and future needs. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 130, 1049-1062.	1.5	486
24	A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor- β Blockade in Severe Persistent Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 549-558.	2.5	444
25	Roflumilastâ€œan oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. <i>Lancet, The</i> , 2005, 366, 563-571.	6.3	443
26	Management of COPD exacerbations: aâ€œEuropean Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 49, 1600791.	3.1	438
27	Risk factors of frequent exacerbations in difficult-to-treat asthma. <i>European Respiratory Journal</i> , 2005, 26, 812-818.	3.1	411
28	An electronic nose in the discrimination ofâ€œpatients with asthma and controls. <i>Journal of Allergy and Clinical Immunology</i> , 2007, 120, 856-862.	1.5	399
29	The Antimicrobial Peptide LL-37 Activates Innate Immunity at the Airway Epithelial Surface by Transactivation of the Epidermal Growth Factor Receptor. <i>Journal of Immunology</i> , 2003, 171, 6690-6696.	0.4	389
30	Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. <i>Lancet, The</i> , 2006, 368, 744-753.	6.3	368
31	An electronic nose in the discrimination ofâ€œpatients with non-small cell lung cancer and COPD. <i>Lung Cancer</i> , 2009, 64, 166-170.	0.9	357
32	Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. <i>New England Journal of Medicine</i> , 2020, 383, 35-48.	13.9	329
33	Factors Associated with Persistent Airflow Limitation in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 744-748.	2.5	311
34	Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 857-866.	6.3	309
35	Chronic sinusitis in severe asthma is related to sputum eosinophilia. <i>Journal of Allergy and Clinical Immunology</i> , 2002, 109, 621-626.	1.5	281
36	Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes, Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19. <i>Immunity</i> , 2020, 53, 1296-1314.e9.	6.6	278

#	ARTICLE	IF	CITATIONS
37	Predicting and evaluating response to omalizumab in patients with severe allergic asthma. <i>Respiratory Medicine</i> , 2007, 101, 1483-1492.	1.3	262
38	Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD. <i>Thorax</i> , 2007, 62, 1081-1087.	2.7	254
39	Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 747-758.	5.2	254
40	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 476-486.	5.2	254
41	Budesonide/Formoterol in a Single Inhaler for Maintenance and Relief in Mild-to-Moderate Asthma. <i>Chest</i> , 2006, 129, 246-256.	0.4	228
42	Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 402-416.	5.2	225
43	Why are long-acting beta-adrenoceptor agonists long-acting?. <i>European Respiratory Journal</i> , 1994, 7, 569-578.	3.1	216
44	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , 2019, 7, 46-59.	5.2	216
45	Endosonography vs Conventional Bronchoscopy for the Diagnosis of Sarcoidosis. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 2457.	3.8	209
46	Antiinflammatory Effects of the Phosphodiesterase-4 Inhibitor Cilomilast (Ariflo) in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 976-982.	2.5	207
47	Refractory Eosinophilic Airway Inflammation in Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004, 170, 601-605.	2.5	206
48	Human Cathelicidin LL-37 Is a Chemoattractant for Eosinophils and Neutrophils That Acts via Formyl-Peptide Receptors. <i>International Archives of Allergy and Immunology</i> , 2006, 140, 103-112.	0.9	201
49	Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. <i>British Journal of Pharmacology</i> , 2011, 163, 53-67.	2.7	201
50	Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 192, 295-306.	2.5	195
51	Systemic Manifestations of COPD. <i>Chest</i> , 2011, 139, 165-173.	0.4	193
52	Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. <i>Lung Cancer</i> , 2007, 56, 25-33.	0.9	190
53	Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018, 27, 180057.	3.0	187
54	Endoscopic Ultrasound-Guided Fine-Needle Aspiration in the Diagnosis and Staging of Lung Cancer and Its Impact on Surgical Staging. <i>Journal of Clinical Oncology</i> , 2005, 23, 8357-8361.	0.8	185

#	ARTICLE	IF	CITATIONS
55	Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma. <i>New England Journal of Medicine</i> , 2021, 385, 1656-1668.	13.9	183
56	Systems medicine and integrated care to combat chronic noncommunicable diseases. <i>Genome Medicine</i> , 2011, 3, 43.	3.6	181
57	Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of <i>Chlamydia pneumoniae</i> infection. <i>Journal of Allergy and Clinical Immunology</i> , 2001, 107, 449-454.	1.5	170
58	Drop-out and attendance in pulmonary rehabilitation: The role of clinical and psychosocial variables. <i>Respiratory Medicine</i> , 2009, 103, 1564-1571.	1.3	168
59	Effect of Fluticasone With and Without Salmeterol on Pulmonary Outcomes in Chronic Obstructive Pulmonary Disease. <i>Annals of Internal Medicine</i> , 2009, 151, 517.	2.0	166
60	An Official American Thoracic Society/European Respiratory Society Statement: Research Questions in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, e4-e27.	2.5	166
61	Inhaled corticosteroids in COPD: friend or foe?. <i>European Respiratory Journal</i> , 2018, 52, 1801219.	3.1	166
62	Rapid KRAS, EGFR, BRAF and PIK3CA Mutation Analysis of Fine Needle Aspirates from Non-Small-Cell Lung Cancer Using Allele-Specific qPCR. <i>PLoS ONE</i> , 2011, 6, e17791.	1.1	166
63	Endoscopic Ultrasound Added to Mediastinoscopy for Preoperative Staging of Patients With Lung Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 931.	3.8	165
64	Asthma transition from childhood into adulthood. <i>Lancet Respiratory Medicine</i> , 2017, 5, 224-234.	5.2	165
65	Airway inflammation in obese and nonobese patients with difficult-to-treat asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 570-574.	2.7	163
66	MACVIA-ARIA Sentinel Network for allergic rhinitis (MASK-rhinitis): the new generation guideline implementation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2015, 70, 1372-1392.	2.7	160
67	Defensins: Key players or bystanders in infection, injury, and repair in the lung? <i>Journal of Allergy and Clinical Immunology</i> , 1999, 104, 1131-1138.	1.5	159
68	Comparison of the Effects of Salmeterol and Formoterol on Airway Tone and Responsiveness over 24 Hours in Bronchial Asthma. <i>The American Review of Respiratory Disease</i> , 1993, 147, 1436-1441.	2.9	157
69	Internet-Based Self-management Plus Education Compared With Usual Care in Asthma. <i>Annals of Internal Medicine</i> , 2009, 151, 110.	2.0	155
70	Integrated care pathways for airway diseases (AIRWAYS-ICPs). <i>European Respiratory Journal</i> , 2014, 44, 304-323.	3.1	154
71	EBUS-TBNA for the diagnosis of central parenchymal lung lesions not visible at routine bronchoscopy. <i>Lung Cancer</i> , 2009, 63, 45-49.	0.9	150
72	The small airways and distal lung compartment in asthma and COPD: a time for reappraisal. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 141-151.	2.7	149

#	ARTICLE	IF	CITATIONS
73	Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 337-344.	5.2	149
74	Neutrophil Defensins Enhance Lung Epithelial Wound Closure and Mucin Gene Expression <i>In Vitro</i> . <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 30, 193-201.	1.4	148
75	Asthma control and differences in management practices across seven European countries. <i>Respiratory Medicine</i> , 2002, 96, 142-149.	1.3	146
76	Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of sarcoidosis. <i>European Respiratory Journal</i> , 2005, 25, 405-409.	3.1	146
77	Transbronchial and transoesophageal (ultrasound-guided) needle aspirations for the analysis of mediastinal lesions. <i>European Respiratory Journal</i> , 2006, 28, 1264-1275.	3.1	146
78	Severe eosinophilic asthma: a roadmap to a consensus. <i>European Respiratory Journal</i> , 2017, 49, 1700634.	3.1	143
79	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015, 45, 879-905.	3.1	138
80	Airway mucosal inflammation in COPD is similar in smokers and ex-smokers: a pooled analysis. <i>European Respiratory Journal</i> , 2007, 30, 467-471.	3.1	135
81	Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 671-678.	2.7	135
82	Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 203, 553-564.	2.5	134
83	Frequent exacerbators "a distinct phenotype of severe asthma. <i>Clinical and Experimental Allergy</i> , 2014, 44, 212-221.	1.4	132
84	Inhibition of eosinophil cyclic nucleotide PDE activity and opsonised zymosan-stimulated respiratory burst by type IV-selective PDE inhibitors. <i>British Journal of Pharmacology</i> , 1991, 103, 1339-1346.	2.7	131
85	Mediastinal restaging: EUS-FNA offers a new perspective. <i>Lung Cancer</i> , 2003, 42, 311-318.	0.9	131
86	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017, 50, 1602265.	3.1	131
87	Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis " A EUFOREA ARIA EPOS AIRWAYS ICP statement. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1297-1305.	2.7	130
88	Alveolar nitric oxide versus measures of peripheral airway dysfunction in severe asthma. <i>European Respiratory Journal</i> , 2006, 27, 951-956.	3.1	129
89	Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. <i>Advances in Therapy</i> , 2018, 35, 737-748.	1.3	129
90	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 367-374.e2.	1.5	128

#	ARTICLE	IF	CITATIONS
91	Markers of disease severity in chronic obstructive pulmonary disease. <i>Pulmonary Pharmacology and Therapeutics</i> , 2006, 19, 189-199.	1.1	127
92	Prioritised research agenda for prevention and control of chronic respiratory diseases. <i>European Respiratory Journal</i> , 2010, 36, 995-1001.	3.1	125
93	Beclometasoneâ€“formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. <i>Lancet Respiratory Medicine</i> , 2013, 1, 23-31.	5.2	125
94	Distribution of inhaled fluticasone propionate between human lung tissue and serum $\langle I \rangle$ in vivo</math>. <i>European Respiratory Journal</i> , 1997, 10, 1496-1499.	3.1	124
95	ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. <i>Clinical and Translational Allergy</i> , 2016, 6, 47.	1.4	121
96	Roflumilast: a review of its use in the treatment of COPD. <i>International Journal of COPD</i> , 2016, 11, 81.	0.9	119
97	Roflumilast with long-acting $\hat{A}2$ -agonists for COPD: influence of exacerbation history. <i>European Respiratory Journal</i> , 2011, 38, 553-560.	3.1	117
98	The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. <i>Respiratory Medicine</i> , 2016, 114, 27-37.	1.3	113
99	Comparison of a Combination of Tiotropium Plus Formoterol to Salmeterol Plus Fluticasone in Moderate COPD. <i>Chest</i> , 2008, 134, 255-262.	0.4	111
100	Effects of cigarette smoke condensate on proliferation and wound closure of bronchial epithelial cells in vitro: role of glutathione. <i>Respiratory Research</i> , 2005, 6, 140.	1.4	110
101	Bronchial Inflammation and Airway Responses to Deep Inspiration in Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 121-128.	2.5	110
102	Exhaled nitric oxide predicts lung function decline in difficult-to-treat asthma. <i>European Respiratory Journal</i> , 2008, 32, 344-349.	3.1	110
103	Extracellular matrix composition in COPD. <i>European Respiratory Journal</i> , 2012, 40, 1362-1373.	3.1	110
104	Mechanisms of cell death induced by the neutrophil antimicrobial peptides $\hat{I}\pm$ -defensins and LL-37. <i>Inflammation Research</i> , 2006, 55, 119-127.	1.6	109
105	Alternative mechanisms for tiotropium. <i>Pulmonary Pharmacology and Therapeutics</i> , 2009, 22, 533-542.	1.1	109
106	Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting $\hat{I}^2₂</sup>$ -Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE²/sup>SPOND). A Randomized Clinical Trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 559-567.	2.5	109
107	EBUS-TBNA for the Clarification of PET Positive Intra-Thoracic Lymph Nodesâ€“an International Multi-Centre Experience. <i>Journal of Thoracic Oncology</i> , 2009, 4, 44-48.	0.5	108
108	Towards a minimally invasive staging strategy in NSCLC: analysis of PET positive mediastinal lesions by EUS-FNA. <i>Lung Cancer</i> , 2004, 44, 53-60.	0.9	107

#	ARTICLE	IF	CITATIONS
109	Increased YKL-40 and Chitotriosidase in Asthma and Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 193, 131-142.	2.5	107
110	Consistency of sputum eosinophilia in difficult-to-treat asthma: A 5-year follow-up study. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 124, 615-617.e2.	1.5	106
111	Efficacy of Roflumilast in the COPD Frequent Exacerbator Phenotype. <i>Chest</i> , 2013, 143, 1302-1311.	0.4	106
112	Initiation of Apoptosis by Actin Cytoskeletal Derangement in Human Airway Epithelial Cells. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2001, 24, 282-294.	1.4	105
113	Diaphragm plication in adult patients with diaphragm paralysis leads to long-term improvement of pulmonary function and level of dyspnea. <i>European Journal of Cardio-thoracic Surgery</i> , 2007, 32, 449-456.	0.6	105
114	Asthma in the elderly: what we know and what we have yet to know. <i>World Allergy Organization Journal</i> , 2014, 7, 8.	1.6	105
115	MASK 2017: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma multimorbidity using real-world-evidence. <i>Clinical and Translational Allergy</i> , 2018, 8, 45.	1.4	104
116	Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 864-879.	1.5	103
117	Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease. <i>Chest</i> , 2018, 153, 888-921.	0.4	102
118	Human neutrophil defensins induce lung epithelial cell proliferation in vitro. <i>Journal of Leukocyte Biology</i> , 2002, 72, 167-74.	1.5	102
119	Burden of non-tuberculous mycobacterial pulmonary disease in Germany. <i>European Respiratory Journal</i> , 2017, 49, 1602109.	3.1	100
120	Theophylline and selective PDE inhibitors as bronchodilators and smooth muscle relaxants. <i>European Respiratory Journal</i> , 1995, 8, 637-42.	3.1	98
121	Poor asthma control in children: evidence from epidemiological surveys and implications for clinical practice. <i>International Journal of Clinical Practice</i> , 2006, 60, 321-334.	0.8	97
122	Is diet partly responsible for differences in COVID-19 death rates between and within countries?. <i>Clinical and Translational Allergy</i> , 2020, 10, 16.	1.4	97
123	EUS-guided FNA of centrally located lung tumours following a non-diagnostic bronchoscopy. <i>Lung Cancer</i> , 2005, 48, 357-361.	0.9	96
124	Effect of the Phosphodiesterase 4 Inhibitor Roflumilast on Glucose Metabolism in Patients with Treatment-Naive, Newly Diagnosed Type 2 Diabetes Mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, E1720-E1725.	1.8	96
125	Cardiovascular Safety in Patients Receiving Roflumilast for the Treatment of COPD. <i>Chest</i> , 2013, 144, 758-765.	0.4	95
126	Mediastinitis Caused by EUS-FNA of a Bronchogenic Cyst. <i>Endoscopy</i> , 2003, 35, 791-793.	1.0	94

#	ARTICLE	IF	CITATIONS
127	Exploring efficacy and safety of oral Pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) - a randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulmonary Medicine, 2017, 17, 122.	0.8	94
128	Eotaxin-2 and eotaxin-3 expression is associated with persistent eosinophilic bronchial inflammation in patients with asthma after allergen challenge. Journal of Allergy and Clinical Immunology, 2005, 115, 779-785.	1.5	92
129	Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 72-80.	2.7	92
130	Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respiratory Medicine, 2005, 99, 1511-1520.	1.3	91
131	Efficacy and Safety of Glycopyrrolate/Formoterol Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Patients With COPD. Chest, 2017, 151, 340-357.	0.4	91
132	Phosphodiesterase-4 Inhibitor Therapy for Lung Diseases. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 271-278.	2.5	90
133	Small airways function and molecular markers in exhaled air in mild asthma. Thorax, 2005, 60, 639-644.	2.7	89
134	Increased number of B-cells in bronchial biopsies in COPD. European Respiratory Journal, 2006, 27, 60-64.	3.1	88
135	Expression of Fas (CD95) and FasL (CD95L) in Human Airway Epithelium. American Journal of Respiratory Cell and Molecular Biology, 1998, 19, 537-542.	1.4	86
136	Update in Chronic Obstructive Pulmonary Disease 2006. American Journal of Respiratory and Critical Care Medicine, 2007, 175, 1222-1232.	2.5	86
137	Smoking cessation and bronchial epithelial remodelling in COPD: a cross-sectional study. Respiratory Research, 2007, 8, 85.	1.4	86
138	Development and implementation of guidelines in allergic rhinitis – an ARIA-GA²LEN paper. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1212-1221.	2.7	85
139	Severe Chronic Allergic (and Related) Diseases: A Uniform Approach – A MeDALL – GA²LEN – ARIA Position Paper. International Archives of Allergy and Immunology, 2012, 158, 216-231.	0.9	83
140	Cabbage and fermented vegetables: From death rate heterogeneity in countries to candidates for mitigation strategies of severe COVID-19. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 735-750.	2.7	83
141	Guidance to 2018 good practice: ARIA digitally-enabled, integrated, person-centred care for rhinitis and asthma. Clinical and Translational Allergy, 2019, 9, 16.	1.4	81
142	Novel concepts of neuropeptide-based drug therapy: Vasoactive intestinal polypeptide and its receptors. European Journal of Pharmacology, 2006, 533, 182-194.	1.7	80
143	Exacerbations of COPD. International Journal of COPD, 2016, 11 Spec Iss, 21.	0.9	79
144	Transcriptional response of bronchial epithelial cells to Pseudomonas aeruginosa: identification of early mediators of host defense. Physiological Genomics, 2005, 21, 324-336.	1.0	77

#	ARTICLE	IF	CITATIONS
145	Mechanisms of Bronchial Hyperreactivity in Asthma and Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2004, 1, 77-87.	3.5	76
146	Combined Analysis of Asthma Safety Trials of Long-Acting β_2 -Agonists. New England Journal of Medicine, 2018, 378, 2497-2505.	13.9	76
147	The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitized human airways. British Journal of Pharmacology, 2000, 131, 1607-1618.	2.7	75
148	Downregulation of the TGF β 2 Pseudoreceptor BAMBI in Non-Small Cell Lung Cancer Enhances TGF β 2 Signaling and Invasion. Cancer Research, 2016, 76, 3785-3801.	0.4	75
149	Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respiratory Medicine, 2021, 9, 1288-1298.	5.2	75
150	Asymptomatic Worsening of Airway Inflammation during Low-Dose Allergen Exposure in Asthma. American Journal of Respiratory and Critical Care Medicine, 2002, 166, 294-300.	2.5	74
151	The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation in the lung. Pulmonary Pharmacology and Therapeutics, 2005, 18, 321-327.	1.1	74
152	Illness Perceptions and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease. Journal of Asthma, 2007, 44, 575-581.	0.9	73
153	Illness Perceptions About Asthma Are Determinants of Outcome. Journal of Asthma, 2008, 45, 459-464.	0.9	73
154	Adherence to treatment in allergic rhinitis using mobile technology. The MASK Study. Clinical and Experimental Allergy, 2019, 49, 442-460.	1.4	73
155	Illness Perceptions and COPD: An Emerging Field for COPD Patient Management. Journal of Asthma, 2008, 45, 625-629.	0.9	72
156	An Official American Thoracic Society/European Respiratory Society Policy Statement: Disparities in Respiratory Health. American Journal of Respiratory and Critical Care Medicine, 2013, 188, 865-871.	2.5	72
157	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. European Respiratory Review, 2015, 24, 159-172.	3.0	72
158	Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and Pre-Existing Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 275-287.	2.5	72
159	Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1994, 266, L536-L543.	1.3	71
160	Correlation between annual change in health status and computer tomography derived lung density in subjects with α 1-antitrypsin deficiency. Thorax, 2003, 58, 1027-1030.	2.7	71
161	Epithelial differentiation is a determinant in the production of eotaxin-2 and -3 by bronchial epithelial cells in response to IL-4 and IL-13. Molecular Immunology, 2007, 44, 803-811.	1.0	71
162	Smoking status and anti-inflammatory macrophages in bronchoalveolar lavage and induced sputum in COPD. Respiratory Research, 2011, 12, 34.	1.4	71

#	ARTICLE	IF	CITATIONS
163	A vision statement on guideline development for respiratory disease: the example of COPD. <i>Lancet</i> , The, 2009, 373, 774-779.	6.3	70
164	Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?. <i>Diagnostic Pathology</i> , 2015, 10, 130.	0.9	70
165	Are Rhinovirus-induced Airway Responses in Asthma Aggravated by Chronic Allergen Exposure?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2003, 168, 1174-1180.	2.5	69
166	Treating COPD â€” The TORCH Trial, P Values, and the Dodo. <i>New England Journal of Medicine</i> , 2007, 356, 851-854.	13.9	69
167	Near-fatal asthma phenotype in the ENFUMOSA Cohort. <i>Clinical and Experimental Allergy</i> , 2007, 37, 552-557.	1.4	69
168	Global Initiative for Chronic Obstructive Lung Disease (GOLD) 20th Anniversary: a brief history of time. <i>European Respiratory Journal</i> , 2017, 50, 1700671.	3.1	69
169	Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. <i>European Respiratory Journal</i> , 2021, 58, 2003393.	3.1	69
170	Predictors of Poor Asthma Control in European Adults. <i>Journal of Asthma</i> , 2003, 40, 803-813.	0.9	67
171	Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 1994, 271, 1167-74.	1.3	67
172	Assessment of Microvascular Leakage via Sputum Induction. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2002, 165, 1275-1279.	2.5	66
173	The antimicrobial peptide LL-37 enhances IL-8 release by human airway smooth muscle cells. <i>Journal of Allergy and Clinical Immunology</i> , 2006, 117, 1328-1335.	1.5	66
174	Transaortic EUS-guided FNA in the diagnosis of lung tumors and lymph nodes. <i>Gastrointestinal Endoscopy</i> , 2009, 69, 345-349.	0.5	66
175	Severity, predictors and clinical correlates of Post-COVID syndrome (PCS) in Germany: A prospective, multi-centre, population-based cohort study. <i>EClinicalMedicine</i> , 2022, 51, 101549.	3.2	66
176	Theophylline suppresses human alveolar macrophage respiratory burst through phosphodiesterase inhibition.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1994, 10, 565-572.	1.4	65
177	Characterisation of exacerbation risk and exacerbator phenotypes in the POET-COPD trial. <i>Respiratory Research</i> , 2013, 14, 116.	1.4	65
178	A prospective clinical study of theophylline safety in 3810 elderly with asthma or COPD. <i>Respiratory Medicine</i> , 2004, 98, 1016-1024.	1.3	64
179	Effects of Î²â€”adrenoceptor agonists in human bronchial smooth muscle. <i>British Journal of Pharmacology</i> , 1993, 110, 1112-1116.	2.7	63
180	Role of Very Late Adhesion Integrins in Mediating Repair of Human Airway Epithelial Cell Monolayers after Mechanical Injury. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1999, 20, 787-796.	1.4	63

#	ARTICLE	IF	CITATIONS
181	A disintegrin and metalloprotease 33 and chronic obstructive pulmonary disease pathophysiology. <i>Thorax</i> , 2007, 62, 242-247.	2.7	63
182	Chronic bronchitis sub-phenotype within COPD: inflammation in sputum and biopsies. <i>European Respiratory Journal</i> , 2008, 31, 70-77.	3.1	63
183	Seasonal Distribution of COPD Exacerbations in the Prevention of Exacerbations With Tiotropium in COPD Trial. <i>Chest</i> , 2013, 143, 711-719.	0.4	63
184	Role of defensins in inflammatory lung disease. <i>Annals of Medicine</i> , 2002, 34, 96-101.	1.5	62
185	Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients. <i>Respiratory Medicine</i> , 2015, 109, 1360-1362.	1.3	62
186	Value of chest radiography in phenotyping chronic obstructive pulmonary disease. <i>European Respiratory Journal</i> , 2008, 31, 509-515.	3.1	61
187	EUS-FNA for the detection of left adrenal metastasis in patients with lung cancer. <i>Lung Cancer</i> , 2011, 73, 310-315.	0.9	61
188	Clinical Correlates of Reduced Physical Activity in Idiopathic Pulmonary Fibrosis. <i>Respiration</i> , 2016, 91, 497-502.	1.2	61
189	Muscarinic M3 receptor stimulation increases cigarette smoke-induced IL-8 secretion by human airway smooth muscle cells. <i>European Respiratory Journal</i> , 2009, 34, 1436-1443.	3.1	60
190	Determinants of Response to Roflumilast in Severe Chronic Obstructive Pulmonary Disease. Pooled Analysis of Two Randomized Trials. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 198, 1268-1278.	2.5	60
191	Controversies in treatment of chronic obstructive pulmonary disease. <i>Lancet, The</i> , 2011, 378, 1038-1047.	6.3	59
192	Sexuality in patients with asthma and COPD. <i>Respiratory Medicine</i> , 2008, 102, 198-204.	1.3	58
193	Chronic obstructive pulmonary disease and exacerbations: Patient insights from the global Hidden Depths of COPD survey. <i>BMC Pulmonary Medicine</i> , 2013, 13, 54.	0.8	58
194	Passive sensitization of human bronchi augments smooth muscle shortening velocity and capacity. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1994, 267, L218-L222.	1.3	57
195	Role of IgE in hyperresponsiveness induced by passive sensitization of human airways.. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1997, 155, 839-844.	2.5	57
196	Expression of smooth muscle and extracellular matrix proteins in relation to airway function in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 1196-1202.	1.5	57
197	How to Integrate Multiple Comorbidities in Guideline Development. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 274-281.	3.5	57
198	Clinical characteristics and possible phenotypes of an adult severe asthma population. <i>Respiratory Medicine</i> , 2012, 106, 47-56.	1.3	57

#	ARTICLE	IF	CITATIONS
199	Nrf2-interacting nutrients and COVID-19: time for research to develop adaptation strategies. <i>Clinical and Translational Allergy</i> , 2020, 10, 58.	1.4	56
200	Markers of exacerbation severity in chronic obstructive pulmonary disease. <i>Respiratory Research</i> , 2006, 7, 74.	1.4	55
201	Small Airways Dysfunction and Neutrophilic Inflammation in Bronchial Biopsies and BAL in COPD. <i>Chest</i> , 2007, 131, 53-59.	0.4	55
202	Sputum Induction in Severe Asthma by a Standardized Protocol. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2001, 164, 749-753.	2.5	54
203	Bronchial matrix and inflammation respond to inhaled steroids despite ongoing allergen exposure in asthma. <i>Clinical and Experimental Allergy</i> , 2005, 35, 1361-1369.	1.4	54
204	Endoscopic ultrasound-guided fine-needle aspiration for the diagnosis of sarcoidosis. <i>Endoscopy</i> , 2010, 42, 213-217.	1.0	54
205	An Official American Thoracic Society/European Respiratory Society Statement: The Role of the Pulmonologist in the Diagnosis and Management of Lung Cancer. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 188, 503-507.	2.5	54
206	Expression of the anaphylatoxin receptors C3aR and C5aR is increased in fatal asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2005, 115, 1148-1154.	1.5	53
207	Lung Function Abnormalities in Smokers with Ischemic Heart Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 568-576.	2.5	53
208	Human alveolar epithelial cells type II are capable of TGF β ² -dependent epithelial-mesenchymal-transition and collagen-synthesis. <i>Respiratory Research</i> , 2018, 19, 138.	1.4	52
209	Characterization of cell surface lectin-binding patterns of human airway epithelium. <i>The Histochemical Journal</i> , 1999, 31, 145-151.	0.6	51
210	Weekly self-monitoring and treatment adjustment benefit patients with partly controlled and uncontrolled asthma: an analysis of the SMASHING study. <i>Respiratory Research</i> , 2010, 11, 74.	1.4	51
211	Do small airway abnormalities characterize asthma phenotypes? In search of proof. <i>Clinical and Experimental Allergy</i> , 2012, 42, 1150-1160.	1.4	51
212	Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis. <i>BMC Pulmonary Medicine</i> , 2017, 17, 104.	0.8	51
213	Does a single dose of the phosphodiesterase 4 inhibitor, cilomilast (15mg), induce bronchodilation in patients with chronic obstructive pulmonary disease?. <i>Pulmonary Pharmacology and Therapeutics</i> , 2003, 16, 115-120.	1.1	50
214	Differential distribution of inflammatory cells in large and small airways in smokers. <i>Journal of Clinical Pathology</i> , 2006, 60, 907-911.	1.0	50
215	The dynamics of illness perceptions: Testing assumptions of Leventhal's common-sense model in a pulmonary rehabilitation setting. <i>British Journal of Health Psychology</i> , 2010, 15, 887-903.	1.9	50
216	Can anti-IgE therapy prevent airway remodeling in allergic asthma?. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2011, 66, 1142-1151.	2.7	50

#	ARTICLE	IF	CITATIONS
217	AIRWAYS-ICPs (European Innovation Partnership on Active and Healthy Ageing) from concept to implementation. <i>European Respiratory Journal</i> , 2016, 47, 1028-1033.	3.1	50
218	Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils. <i>European Respiratory Journal</i> , 2018, 51, 1700970.	3.1	49
219	The Efficacy and Safety of Cilomilast in COPD. <i>Drugs</i> , 2008, 68, 3-57.	4.9	48
220	Endoscopic Lung Volume Reduction: An Expert Panel Recommendation. <i>Respiration</i> , 2016, 91, 241-250.	1.2	48
221	Cyclic Nucleotide Phosphodiesterase in Human Bronchial Epithelial Cells: Characterization of Isoenzymes and Functional Effects of PDE Inhibitors. <i>Pulmonary Pharmacology and Therapeutics</i> , 1998, 11, 47-56.	1.1	47
222	Scaling up strategies of the chronic respiratory disease programme of the European Innovation Partnership on Active and Healthy Ageing (Action Plan B3: Area 5). <i>Clinical and Translational Allergy</i> , 2016, 6, 29.	1.4	47
223	Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma. <i>Pulmonary Pharmacology and Therapeutics</i> , 2017, 45, 121-123.	1.1	47
224	Illness perceptions and quality of life in Japanese and Dutch patients with non-small-cell lung cancer. <i>Lung Cancer</i> , 2011, 72, 384-390.	0.9	46
225	Anti-inflammatory effects of roflumilast in chronic obstructive pulmonary disease (ROBERT): a 16-week, randomised, placebo-controlled trial. <i>Lancet Respiratory Medicine</i> , 2018, 6, 827-836.	5.2	46
226	Salmeterol is a competitive antagonist at β_2 -adrenoceptors mediating inhibition of respiratory burst in guinea-pig eosinophils. <i>European Journal of Pharmacology</i> , 1993, 231, 305-308.	1.7	45
227	Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 527-539.e9.	2.0	45
228	Immune mechanisms of smooth muscle hyperreactivity in asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2000, 105, 673-682.	1.5	44
229	Comparison of exhaled breath condensate pH using two commercially available devices in healthy controls, asthma and COPD patients. <i>Respiratory Research</i> , 2009, 10, 78.	1.4	44
230	Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. <i>Lancet Respiratory Medicine</i> , 2014, 2, 44-53.	5.2	44
231	Physical activity, airway resistance and small airway dysfunction in severe asthma. <i>European Respiratory Journal</i> , 2017, 49, 1601827.	3.1	44
232	The all age asthma cohort (ALLIANCE) - from early beginnings to chronic disease: a longitudinal cohort study. <i>BMC Pulmonary Medicine</i> , 2018, 18, 140.	0.8	44
233	Economic burden of bronchiectasis in Germany. <i>European Respiratory Journal</i> , 2019, 53, 1802033.	3.1	44
234	Further evidence that tachykinin-induced contraction of human isolated bronchus is mediated only by NK2-receptors. <i>Neuropeptides</i> , 1995, 29, 281-292.	0.9	43

#	ARTICLE	IF	CITATIONS
235	State of the art lecture: EUS and EBUS in pulmonary medicine. <i>Endoscopy</i> , 2006, 38, 118-122.	1.0	43
236	Densitometry for assessment of effect of lung volume reduction surgery for emphysema. <i>European Respiratory Journal</i> , 2007, 29, 1138-1143.	3.1	43
237	Implementation of endoscopic ultrasound for lung cancer staging. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 64-70.e1.	0.5	43
238	Toll-Like Receptor (TLR2 and TLR4) Polymorphisms and Chronic Obstructive Pulmonary Disease. <i>PLoS ONE</i> , 2012, 7, e43124.	1.1	43
239	Roflumilast for asthma: Efficacy findings in mechanism of action studies. <i>Pulmonary Pharmacology and Therapeutics</i> , 2015, 35, S4-S10.	1.1	43
240	Subclinical impairment of lung function is related to mild cardiac dysfunction and manifest heart failure in the general population. <i>International Journal of Cardiology</i> , 2016, 218, 298-304.	0.8	43
241	Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1993, 264, L458-L464.	1.3	42
242	Passive sensitization of human airways induces myogenic contractile responses in vitro. <i>Journal of Applied Physiology</i> , 1997, 83, 1276-1281.	1.2	42
243	Passive sensitization of human airways increases responsiveness to leukotriene C4. <i>European Respiratory Journal</i> , 1999, 14, 315-319.	3.1	42
244	Host defense effector molecules in mucosal secretions. <i>FEMS Immunology and Medical Microbiology</i> , 2005, 45, 151-158.	2.7	42
245	Safety of long-acting β -agonists: urgent need to clear the air remains. <i>European Respiratory Journal</i> , 2009, 33, 3-5.	3.1	42
246	Fas cross-linking induces apoptosis in human airway smooth muscle cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2000, 278, L618-L624.	1.3	41
247	T cells and eosinophils in bronchial smooth muscle cell death in asthma. <i>Clinical and Experimental Allergy</i> , 2009, 39, 845-855.	1.4	41
248	Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial. <i>Pulmonary Pharmacology and Therapeutics</i> , 2019, 56, 86-93.	1.1	41
249	The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. <i>Lancet Respiratory Medicine</i> , 2022, 10, 661-668.	5.2	41
250	50 Years of psychological research on patients with COPD – “Road to ruin or highway to heaven?”. <i>Respiratory Medicine</i> , 2009, 103, 3-11.	1.3	40
251	FEV1 and FVC predict all-cause mortality independent of cardiac function – “Results from the population-based Gutenberg Health Study. <i>International Journal of Cardiology</i> , 2017, 234, 64-68.	0.8	40
252	Cost-Effectiveness of Internet-Based Self-Management Compared with Usual Care in Asthma. <i>PLoS ONE</i> , 2011, 6, e27108.	1.1	40

#	ARTICLE	IF	CITATIONS
253	Cyclic nucleotide phosphodiesterases in the human lung. <i>Lung</i> , 1994, 172, 129-46.	1.4	39
254	TGF- β 2 differentially regulates TH2 cytokine-induced eotaxin and eotaxin-3 release by human airway smooth muscle cells. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 791-798.	1.5	39
255	Cost of scheduled and unscheduled asthma management in seven European Union countries. <i>European Respiratory Review</i> , 2006, 15, 4-9.	3.0	39
256	Effect of roflumilast in patients with severe COPD and a history of hospitalisation. <i>European Respiratory Journal</i> , 2017, 50, 1700158.	3.1	39
257	Rhinovirus infections change DNA methylation and mRNA expression in children with asthma. <i>PLoS ONE</i> , 2018, 13, e0205275.	1.1	39
258	Small Airway Dysfunction Links Asthma Severity with Physical Activity and Symptom Control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3359-3368.e1.	2.0	39
259	The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. <i>Respiratory Research</i> , 2012, 13, 59.	1.4	37
260	Transesophageal Ultrasound-Guided Fine-Needle Aspiration for the Mediastinal Restaging of Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 1510-1515.	0.5	36
261	IL-4 and IL-13 exposure during mucociliary differentiation of bronchial epithelial cells increases antimicrobial activity and expression of antimicrobial peptides. <i>Respiratory Research</i> , 2011, 12, 59.	1.4	36
262	Lipidomes of lung cancer and tumour-free lung tissues reveal distinct molecular signatures for cancer differentiation, age, inflammation, and pulmonary emphysema. <i>Scientific Reports</i> , 2017, 7, 11087.	1.6	36
263	Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. <i>ERJ Open Research</i> , 2020, 6, 00204-2019.	1.1	36
264	Recommendations on Inpatient Treatment of Patients With COVID-19. <i>Deutsches A&#x0308;rztblatt International</i> , 2021, 118, .	0.6	35
265	Inhibition of Human Airway Sensitization by a Novel Monoclonal Anti-IgE Antibody, 17-9. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 157, 1429-1435.	2.5	34
266	Proliferation and inflammation in bronchial epithelium after allergen in atopic asthmatics. <i>Clinical and Experimental Allergy</i> , 2003, 33, 905-911.	1.4	34
267	Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. <i>European Respiratory Journal</i> , 1998, 11, 617-23.	3.1	34
268	Improving Dyspnea in Chronic Obstructive Pulmonary Disease: Optimal Treatment Strategies. <i>Proceedings of the American Thoracic Society</i> , 2006, 3, 270-275.	3.5	33
269	Update in Chronic Obstructive Pulmonary Disease 2005. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006, 173, 1056-1065.	2.5	33
270	Patients cured from craniopharyngioma or nonfunctioning pituitary macroadenoma (NFMA) suffer similarly from increased daytime somnolence despite normal sleep patterns compared to healthy controls. <i>Clinical Endocrinology</i> , 2008, 69, 769-774.	1.2	33

#	ARTICLE	IF	CITATIONS
271	Predominance of left-sided deep vein thrombosis and body weight. <i>Journal of Thrombosis and Haemostasis</i> , 2010, 8, 2083-2084.	1.9	33
272	Effect of proinflammatory cytokines on interleukin-8 mRNA expression and protein production by isolated human alveolar epithelial cells type II in primary culture. <i>European Cytokine Network</i> , 2000, 11, 618-25.	1.1	33
273	Lymphocytic inflammation in childhood bronchiolitis obliterans. <i>Pediatric Pulmonology</i> , 2004, 38, 233-239.	1.0	32
274	The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2006, 61, 1097-1103.	2.7	32
275	Variability of bronchial inflammation in chronic obstructive pulmonary disease: implications for study design. <i>European Respiratory Journal</i> , 2006, 27, 293-299.	3.1	32
276	Chicken or egg: physical activity in COPD revisited. <i>European Respiratory Journal</i> , 2008, 33, 227-229.	3.1	32
277	Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air App. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1672-1688.	2.7	32
278	Protein Kinase C Inhibition Enhances Platelet-activating Factor-induced Eicosanoid Production in Human Eosinophils. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1998, 18, 136-144.	1.4	31
279	Migration of human and guinea pig airway epithelial cells in response to calcitonin gene-related peptide.. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 1994, 11, 181-187.	1.4	30
280	Efficacy of the novel phosphodiesterase-4 inhibitor BAY 19-8004 on lung function and airway inflammation in asthma and chronic obstructive pulmonary disease (COPD). <i>Pulmonary Pharmacology and Therapeutics</i> , 2003, 16, 341-347.	1.1	30
281	Rapid, reliable and responsive: for whom?. <i>European Respiratory Journal</i> , 2004, 23, 1-2.	3.1	30
282	Pulmonary periarterial inflammation in fatal asthma. <i>Clinical and Experimental Allergy</i> , 2009, 39, 1499-1507.	1.4	30
283	Mediastinal-esophageal fistulae after EUS-FNA of tuberculosis of the mediastinum. <i>Gastrointestinal Endoscopy</i> , 2010, 71, 210-212.	0.5	30
284	Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? the REACT study protocol. <i>International Journal of COPD</i> , 2012, 7, 375.	0.9	30
285	Concerns About Exercise Are Related to Walk Test Results in Pulmonary Rehabilitation for Patients with COPD. <i>International Journal of Behavioral Medicine</i> , 2012, 19, 39-47.	0.8	30
286	Association of lung function measurements and visceral fat in men with metabolic syndrome. <i>Respiratory Medicine</i> , 2014, 108, 351-357.	1.3	30
287	Airway pathology in severe asthma is related to airflow obstruction but not symptom control. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 635-643.	2.7	30
288	Key summary of German national treatment guidance for hospitalized COVID-19 patients. <i>Infection</i> , 2022, 50, 93-106.	2.3	30

#	ARTICLE	IF	CITATIONS
289	Exhaled nitric oxide in COPD: glancing through a smoke screen. <i>Thorax</i> , 1999, 54, 565-567.	2.7	29
290	Pharmacological treatment of asthma today. <i>European Respiratory Journal</i> , 2001, 18, 34-40.	3.1	29
291	The EvA study: aims and strategy. <i>European Respiratory Journal</i> , 2012, 40, 823-829.	3.1	29
292	A Guide to Guidelines for Professional Societies and Other Developers of Recommendations. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 215-218.	3.5	29
293	The use of auto-antibody testing in the evaluation of interstitial lung disease (ILD) – A practical approach for the pulmonologist. <i>Respiratory Medicine</i> , 2016, 113, 80-92.	1.3	29
294	Characterisation of the endothelin receptor mediating contraction of human pulmonary artery using BQ123 and Ro 46-2005. <i>European Journal of Pharmacology</i> , 1994, 260, 221-225.	1.7	28
295	You've got mail: erj@lumc.nl. <i>European Respiratory Journal</i> , 2003, 21, 1-2.	3.1	28
296	Longitudinal Impact of Sputum Inflammatory Phenotypes on Small Airway Dysfunction and Disease Outcomes in Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 1545-1553.e2.	2.0	28
297	Animal Models for Human Asthma: The Perspective of a Clinician. <i>Current Drug Targets</i> , 2008, 9, 438-442.	1.0	27
298	Endosonography for Lung Cancer Staging. <i>Chest</i> , 2010, 138, 765-767.	0.4	27
299	EUS-FNA in the preoperative staging of non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 69, 60-65.	0.9	27
300	A phase III study of triple therapy with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler 320/18/9.6µg and 160/18/9.6µg using co-suspension delivery technology in moderate-to-very severe COPD: The ETHOS study protocol. <i>Respiratory Medicine</i> , 2019, 158, 59-66.	1.3	27
301	Hydrogen peroxide contracts human airways in vitro: role of epithelium. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1995, 269, L332-L338.	1.3	26
302	Inherent tone of human bronchus: role of eicosanoids and the epithelium. <i>British Journal of Pharmacology</i> , 1997, 121, 1099-1104.	2.7	26
303	Deficient alpha-1-antitrypsin phenotypes and persistent airflow limitation in severe asthma. <i>Respiratory Medicine</i> , 2006, 100, 1534-1539.	1.3	26
304	Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2015, 10, 549.	0.9	26
305	Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function. <i>International Journal of COPD</i> , 2017, Volume 12, 981-987.	0.9	26
306	High-sensitivity troponin I and all-cause mortality in patients with stable COPD: an analysis of the COSYCONET study. <i>European Respiratory Journal</i> , 2020, 55, 1901314.	3.1	26

#	ARTICLE	IF	CITATIONS
307	The Multi-Modal Effect of the Anti-fibrotic Drug Pirfenidone on NSCLC. <i>Frontiers in Oncology</i> , 2019, 9, 1550.	1.3	26
308	Reproducibility of airway response to inhaled bradykinin and effect of the neurokinin receptor antagonist FK-24 in asthmatic subjects. <i>European Journal of Clinical Pharmacology</i> , 1996, 50, 269-273.	0.8	25
309	Histamine hypersensitivity induced by passive sensitization of human bronchus: effect of serum IgE depletion. <i>Clinical and Experimental Allergy</i> , 1998, 28, 679-685.	1.4	25
310	Serum immunoglobulin E levels predict human airway reactivity in vitro. <i>Clinical and Experimental Allergy</i> , 2000, 30, 233-241.	1.4	25
311	The effect of the enantiomers of formoterol on inherent and induced tone in guinea-pig trachea and human bronchus. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2000, 361, 405-409.	1.4	25
312	The Role of Leukotrienes in the Regulation of Tone and Responsiveness in Isolated Human Airways. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000, 161, S62-S67.	2.5	25
313	The effect of the vasoactive intestinal polypeptide agonist Ro 25-1553 on induced tone in isolated human airways and pulmonary artery. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2001, 364, 314-320.	1.4	25
314	Patient preferences for asthma therapy: a discrete choice experiment. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2007, 16, 241-248.	2.5	25
315	Anticholinergic Drugs for the Treatment of COPD Are Safe? Are They?. <i>Chest</i> , 2010, 137, 1-3.	0.4	25
316	Small airway dysfunction as predictor and marker for clinical response to biological therapy in severe eosinophilic asthma: a longitudinal observational study. <i>Respiratory Research</i> , 2020, 21, 278.	1.4	25
317	Mechanisms of Immune Sensitization of Human Bronchus. <i>American Journal of Respiratory and Critical Care Medicine</i> , 1998, 158, S161-S170.	2.5	24
318	Human neutrophil defensins and secretory leukocyte proteinase inhibitor in squamous metaplastic epithelium of bronchial airways. <i>Inflammation Research</i> , 2004, 53, 230-238.	1.6	24
319	Salmeterol protects against hyperventilation-induced bronchoconstriction over 12 hours. <i>European Journal of Clinical Pharmacology</i> , 1992, 43, 591-595.	0.8	23
320	The relevance of resting tension to responsiveness and inherent tone of human bronchial smooth muscle. <i>British Journal of Pharmacology</i> , 1998, 123, 694-700.	2.7	23
321	Five good reasons to read (and cite) the ERJ. <i>European Respiratory Journal</i> , 2008, 31, 1-2.	3.1	23
322	CD8+ T cells characterize early smoking-related airway pathology in patients with asthma. <i>Respiratory Medicine</i> , 2013, 107, 959-966.	1.3	23
323	Unmet needs for the assessment of small airways dysfunction in asthma: introduction to the ATLANTIS study. <i>European Respiratory Journal</i> , 2015, 45, 1534-1538.	3.1	23
324	Antagonism of β_2 -adrenoceptor-mediated relaxations of human bronchial smooth muscle by carbachol. <i>European Journal of Pharmacology</i> , 1995, 275, 307-310.	1.7	22

#	ARTICLE	IF	CITATIONS
325	Histologic Patterns of Lung Infiltration of B-Cell, T-Cell, and Hodgkin Lymphomas. American Journal of Clinical Pathology, 2004, 121, 718-726.	0.4	22
326	Nebulised budesonide using a novel device in patients with oral steroid-dependent asthma. European Respiratory Journal, 2015, 45, 1273-1282.	3.1	22
327	Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids. European Respiratory Journal, 2017, 49, 1600839.	3.1	22
328	Physical Activity and Fatigue in Patients with Sarcoidosis. Respiration, 2018, 95, 18-26.	1.2	22
329	Augmentation of human neutrophil and alveolar macrophage LTB4 production by N -acetylcysteine: role of hydrogen peroxide. British Journal of Pharmacology, 1997, 122, 758-764.	2.7	21
330	Summary of recommendations for the design of clinical trials and the registration of drugs used in the treatment of asthma. Respiratory Medicine, 2004, 98, 479-487.	1.3	21
331	Guidelines for Chronic Obstructive Pulmonary Disease Treatment and Issues of Implementation. Proceedings of the American Thoracic Society, 2006, 3, 641-644.	3.5	21
332	Roflumilast for the treatment of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2010, 4, 543-555.	1.0	21
333	A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension [®] , [®] Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 8.	1.4	21
334	Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD. International Journal of COPD, 2018, Volume 13, 813-822.	0.9	21
335	Migration and proliferation of guinea pig and human airway epithelial cells in response to tachykinins. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1995, 269, L119-L126.	1.3	20
336	Leukotrienes as Targets for Treatment of Asthma and Other Diseases. American Journal of Respiratory and Critical Care Medicine, 2000, 161, S1-S1.	2.5	20
337	Pharmacological basis for duration of effect: Formoterol and salmeterol versus short-acting β_2 -adrenoceptor agonists. Lung, 2004, 174, 1-22.	1.4	20
338	Transesophageal endoscopic ultrasound-guided fine-needle aspiration for the mediastinal staging of extrathoracic tumors: a new perspective. Annals of Oncology, 2010, 21, 1468-1471.	0.6	20
339	Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients. Respiratory Medicine, 2013, 107, 75-83.	1.3	20
340	Multi-analyte profiling of inflammatory mediators in COPD sputum – The effects of processing. Cytokine, 2015, 71, 401-404.	1.4	20
341	Screening for <i>Helicobacter pylori</i> in Idiopathic Pulmonary Fibrosis Lung Biopsies. Respiration, 2016, 91, 3-8.	1.2	20
342	Role of dual bronchodilators in COPD: A review of the current evidence for indacaterol/glycopyrronium. Pulmonary Pharmacology and Therapeutics, 2017, 45, 19-33.	1.1	20

#	ARTICLE	IF	CITATIONS
343	The challenge of long-acting β_2 -adrenoceptor agonists. <i>Respiratory Medicine</i> , 1991, 85, 5-9.	1.3	19
344	Contraction of human bronchial smooth muscle caused by activated human eosinophils. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1994, 267, L326-L334.	1.3	19
345	Editing the ERJ: an observational study. <i>European Respiratory Journal</i> , 2006, 27, 1-2.	3.1	19
346	Dupilumab Reduces Oral Corticosteroid Use in Patients With Corticosteroid-Dependent Severe Asthma. <i>Chest</i> , 2022, 162, 46-55.	0.4	19
347	Why Respiratory Physicians Should Learn and Implement EUS-FNA. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 99-99.	2.5	18
348	High-affinity immunoglobulin E receptor expression is increased in large and small airways in fatal asthma. <i>Clinical and Experimental Allergy</i> , 2010, 40, 1473-1481.	1.4	18
349	An official American Thoracic Society and European Respiratory Society policy statement: disparities in respiratory health. <i>European Respiratory Journal</i> , 2013, 42, 906-915.	3.1	18
350	Nasal Levels of Antimicrobial Peptides in Allergic Asthma Patients and Healthy Controls: Differences and Effect of a Short 1,25(OH) ₂ Vitamin D ₃ Treatment. <i>PLoS ONE</i> , 2015, 10, e0140986.	1.1	18
351	RNA-seq-based profiling of extracellular vesicles in plasma reveals a potential role of miR-122-5p in asthma. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 366-371.	2.7	18
352	Neutrophil influx into guinea pig airway lumen during cholinergic and non-cholinergic bronchoconstriction. <i>Acta Physiologica Scandinavica</i> , 1992, 144, 101-106.	2.3	17
353	A rare cause of Ortner's syndrome (cardiovocal hoarseness). <i>Thorax</i> , 2004, 59, 636-636.	2.7	17
354	Bronchopulmonary lymph nodes and large airway cell trafficking in patients with fatal asthma. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 1352-1357.e9.	1.5	17
355	Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 377, 1997-1999.	13.9	17
356	The Relevance of Small Airway Dysfunction in Asthma with Nocturnal Symptoms. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 897-905.	1.5	17
357	Eosinophil VLA-4 binding to fibronectin augments bronchial narrowing through 5-lipoxygenase activation. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1996, 270, L587-L594.	1.3	16
358	Palliative Care Concepts in Respiratory Disease. <i>Respiration</i> , 2011, 82, 483-491.	1.2	16
359	Increased expression of granzymes A and B in fatal asthma. <i>European Respiratory Journal</i> , 2015, 45, 1485-1488.	3.1	16
360	Identification of novel target genes in human lung tissue involved in chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2018, Volume 13, 2255-2259.	0.9	16

#	ARTICLE	IF	CITATIONS
361	Live and let die: epigenetic modifications of Survivin and Regucalcin in non-small cell lung cancer tissues contribute to malignancy. <i>Clinical Epigenetics</i> , 2019, 11, 157.	1.8	16
362	Lung function fluctuation patterns unveil asthma and COPD phenotypes unrelated to type 2 inflammation. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 407-419.	1.5	16
363	Reduced microRNA-503 expression augments lung fibroblast VEGF production in chronic obstructive pulmonary disease. <i>PLoS ONE</i> , 2017, 12, e0184039.	1.1	16
364	Analysis of Subcarinal Lymph Nodes in (Suspected) Non-Small-Cell Lung Cancer after a Negative Transbronchial Needle Aspiration – What’s Next?. <i>Respiration</i> , 2004, 71, 630-634.	1.2	15
365	Burden of asthma in the hospital setting: an Australian analysis. <i>International Journal of Clinical Practice</i> , 2007, 61, 1884-1888.	0.8	15
366	Surgical Technique of Lower Lobe Lung Transplantation. <i>Annals of Thoracic Surgery</i> , 2011, 92, e39-e42.	0.7	15
367	Controlled and uncontrolled allergic asthma in routine respiratory specialist care – a clinical epidemiological study in Germany. <i>Current Medical Research and Opinion</i> , 2011, 27, 1835-1847.	0.9	15
368	The European Respiratory Society plans its future: the 2013-2018 strategic plan. <i>European Respiratory Journal</i> , 2014, 43, 927-932.	3.1	15
369	Can severe asthmatic patients achieve asthma control? A systematic approach in patients with difficult to control asthma followed in a specialized clinic. <i>BMC Pulmonary Medicine</i> , 2016, 16, 153.	0.8	15
370	Peripheral eosinophil count as a biomarker for the management of COPD: not there yet. <i>European Respiratory Journal</i> , 2017, 50, 1702165.	3.1	15
371	Comparison of PD-L1 expression between paired cytologic and histologic specimens from non-small cell lung cancer patients. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 476, 261-271.	1.4	15
372	COL4A3 is degraded in allergic asthma and degradation predicts response to anti-IgE therapy. <i>European Respiratory Journal</i> , 2021, 58, 2003969.	3.1	15
373	Persistent Uncontrolled Asthma: Long-Term Impact on Physical Activity and Body Composition. <i>Journal of Asthma and Allergy</i> , 2021, Volume 14, 229-240.	1.5	14
374	Selective phosphodiesterase inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2002, 2, 61-67.	1.1	13
375	Reporting and Publishing Guidelines. <i>Proceedings of the American Thoracic Society</i> , 2012, 9, 293-297.	3.5	13
376	HOPE-preservation of paraffin-embedded sputum samples – A new way of bioprofiling in COPD. <i>Respiratory Medicine</i> , 2013, 107, 587-595.	1.3	13
377	Reprogramming of COPD lung fibroblasts through formation of induced pluripotent stem cells. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014, 306, L552-L565.	1.3	13
378	Chronic obstructive pulmonary disease and exacerbations: clinician insights from the global Hidden Depths of COPD survey. <i>Current Medical Research and Opinion</i> , 2014, 30, 667-684.	0.9	13

#	ARTICLE	IF	CITATIONS
379	Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial. <i>Respiratory Research</i> , 2020, 21, 177.	1.4	13
380	Alveolar macrophages from bronchoalveolar lavage of patients with pulmonary histiocytosis X: Determination of phenotypic and functional changes. <i>Lung</i> , 1995, 173, 187-95.	1.4	12
381	Effects of a Selective PDE4 Inhibitor, D-22888, on Human Airways and Eosinophils in vitro and Late Phase Allergic Pulmonary Eosinophilia in Guinea Pigs. <i>Pulmonary Pharmacology and Therapeutics</i> , 1998, 11, 13-21.	1.1	12
382	Formoterol in clinical practice—safety issues. <i>Respiratory Medicine</i> , 2001, 95, S21-S25.	1.3	12
383	Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist. <i>European Radiology</i> , 2004, 14, 2030-2037.	2.3	12
384	Obtaining optimal control in mild asthma: theory and practice. <i>Family Practice</i> , 2005, 22, 305-310.	0.8	12
385	A molecular signature of epithelial host defense: comparative gene expression analysis of cultured bronchial epithelial cells and keratinocytes. <i>BMC Genomics</i> , 2006, 7, 9.	1.2	12
386	Implementing lessons learned from previous bronchial biopsy trials in a new randomized controlled COPD biopsy trial with roflumilast. <i>BMC Pulmonary Medicine</i> , 2014, 14, 9.	0.8	12
387	Cryobiopsy for Interstitial Lung Disease: The Heat Is On. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1183-1184.	2.5	12
388	<p>Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2993-3002.	0.9	12
389	<p>Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study</p>. <i>International Journal of COPD</i> , 2019, Volume 14, 2979-2991.	0.9	12
390	Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. <i>Respiratory Medicine</i> , 2021, 185, 106509.	1.3	12
391	Immune cell profile in infants' lung tissue. <i>Annals of Anatomy</i> , 2013, 195, 596-604.	1.0	11
392	Assessing small airway impairment in mild-to-moderate smoking asthmatic patients. <i>European Respiratory Journal</i> , 2016, 47, 1264-1267.	3.1	11
393	Effects of airway obstruction and hyperinflation on electrocardiographic axes in COPD. <i>Respiratory Research</i> , 2019, 20, 61.	1.4	11
394	Sex dependent effect of maternal e-nicotine on F1 <i>Drosophila</i> development and airways. <i>Scientific Reports</i> , 2021, 11, 4441.	1.6	11
395	Improvements in lung function with budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler <i>versus</i> dual therapies in patients with COPD: a sub-study of the ETHOS trial. <i>Therapeutic Advances in Respiratory Disease</i> , 2021, 15, 175346662110343.	1.0	11
396	Isolated, Electrically-stimulated Airway Preparations—Their Use in Determining β_2 -Adrenoceptor Agonist Activity. <i>Pulmonary Pharmacology</i> , 1996, 9, 107-117.	0.5	10

#	ARTICLE	IF	CITATIONS
397	Up-regulation of human eosinophil leukotriene C 4 generation through contact with bronchial epithelial cells. <i>Inflammation Research</i> , 2000, 49, 236-239.	1.6	10
398	What else can you expect at www.erj.ersjournals.com ?. <i>European Respiratory Journal</i> , 2006, 29, 1-3.	3.1	10
399	Somatostatin analog treatment is associated with an increased sleep latency in patients with long-term biochemical remission of acromegaly. <i>Growth Hormone and IGF Research</i> , 2008, 18, 446-453.	0.5	10
400	Drug Safety in COPD Revisited. <i>Chest</i> , 2012, 142, 271-274.	0.4	10
401	Pulmonologists and lung cancer: pivotal role in multidisciplinary approach. <i>European Respiratory Journal</i> , 2013, 42, 1183-1185.	3.1	10
402	Anti-inflammatory effects of budesonide in human lung fibroblasts are independent of histone deacetylase 2. <i>Journal of Inflammation Research</i> , 2013, 6, 109.	1.6	10
403	Angiopietin-like protein 4 and cardiovascular function in COPD. <i>BMJ Open Respiratory Research</i> , 2016, 3, e000161.	1.2	10
404	Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO® Trials. <i>Advances in Therapy</i> , 2021, 38, 579-593.	1.3	10
405	Raised sputum extracellular DNA confers lung function impairment and poor symptom control in an exacerbation-susceptible phenotype of neutrophilic asthma. <i>Respiratory Research</i> , 2021, 22, 167.	1.4	10
406	Late Breaking Abstract - Exploring Efficacy and Safety of oral Pirfenidone for progressive, non-IPF Lung Fibrosis (RELIEF). , 2019, , .		10
407	Plasma proteins elevated in severe asthma despite oral steroid use and unrelated to Type-2 inflammation. <i>European Respiratory Journal</i> , 2022, 59, 2100142.	3.1	10
408	Predictive modeling of COPD exacerbation rates using baseline risk factors. <i>Therapeutic Advances in Respiratory Disease</i> , 2022, 16, 175346662211073.	1.0	10
409	Low dose fenoterol aerosol protects against histamine-induced bronchoconstriction in mild asthmatics: a dose response study. <i>Clinical and Experimental Allergy</i> , 1992, 22, 690-693.	1.4	9
410	Involvement of protein tyrosine kinases in activation of human eosinophils by platelet-activating factor. <i>Immunology</i> , 2000, 100, 231-237.	2.0	9
411	Attenuation of Inhibitory Prostaglandin E2 Signaling in Human Lung Fibroblasts Is Mediated by Phosphodiesterase 4. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2012, 47, 729-737.	1.4	9
412	Global Initiative on Obstructive Lung Disease Revised. What Constitutes a Guideline?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013, 187, 1035-1036.	2.5	9
413	Respiratory diseases in the world: one voice "united for lung health". <i>European Respiratory Journal</i> , 2014, 43, 3-5.	3.1	9
414	Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β_2 -agonist fixed-dose combination: Rationale and study design. <i>International Journal of COPD</i> , 2016, Volume 11, 1921-1928.	0.9	9

#	ARTICLE	IF	CITATIONS
415	Effects of Theophylline and Non-selective Xanthine Derivatives on PDE Isoenzymes and Cellular Function. , 1996, , 41-64.		9
416	Anwendung von Biologika bei allergischen und Typ-2- entzündlichen Erkrankungen in der aktuellen COVID-19-Pandemie – ein Positionspapier von AeDA, DGAKI, GPA, –GAI, LGAI, –GP, ARIA und EAACI. Allergologie, 2020, 43, 255-271.	0.1	9
417	Augmentation of eosinophil degranulation and LTC ₄ secretion by integrin-mediated endothelial cell adhesion. American Journal of Physiology - Lung Cellular and Molecular Physiology, 1999, 277, L802-L810.	1.3	8
418	Bilateral Cavitory Pulmonary Consolidations in a Patient Undergoing Allogeneic Bone Marrow Transplantation for Acute Leukemia. Chest, 2003, 123, 929-934.	0.4	8
419	Exploring host-pathogen interactions at the epithelial surface: application of transcriptomics in lung biology. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2007, 292, L367-L377.	1.3	8
420	Avalia –o dos resultados nos ensaios cl –nicos na DPOC: Da fun –o pulmonar aos marcadores biol –gicos. Revista Portuguesa De Pneumologia, 2008, 14, 579-583.	0.7	8
421	Fountain of youth for squamous cell carcinomas? On the epigenetic age of non –small cell lung cancer and corresponding tumor –free lung tissues. International Journal of Cancer, 2018, 143, 3061-3070.	2.3	8
422	Breath volatile organic compounds and inflammatory markers in adult asthma patients: negative results from the ALLIANCE cohort. European Respiratory Journal, 2021, 57, 2002127.	3.1	8
423	DNA methylation profiles of bronchoscopic biopsies for the diagnosis of lung cancer. Clinical Epigenetics, 2021, 13, 38.	1.8	8
424	Variability in Aerosol Output of the DeVilbiss 646 Jet Nebulizer. Chest, 1992, 102, 1636.	0.4	7
425	The effect of 10, 50 and 200 mug inhaled fenoterol on exercise induced asthma. Clinical and Experimental Allergy, 1993, 23, 440-445.	1.4	7
426	Conservation of bronchiolar wall area during constriction and dilation of human airways. Journal of Applied Physiology, 1997, 82, 954-958.	1.2	7
427	Studying human airway pharmacology in microsections: application of videomicroscopy. European Respiratory Journal, 2002, 19, 991-996.	3.1	7
428	Combination therapy for chronic obstructive pulmonary disease: one size fits all?. European Respiratory Journal, 2003, 22, 874-875.	3.1	7
429	Roflumilast for chronic obstructive pulmonary disease – Author's reply. Lancet, The, 2005, 366, 1846-1847.	6.3	7
430	Theophylline for Chronic Obstructive Pulmonary Disease? – Time to Move On. American Journal of Respiratory and Critical Care Medicine, 2010, 182, 868-869.	2.5	7
431	The Year of the Lung. Lancet, The, 2010, 376, 753-754.	6.3	7
432	2010: the Year of the Lung. European Respiratory Journal, 2011, 37, 1-2.	3.1	7

#	ARTICLE	IF	CITATIONS
433	Uncovering and tackling Europe's hidden respiratory illness. <i>Lancet</i> , The, 2012, 380, 623-624.	6.3	7
434	The Aging Lung: Clinical and Imaging Findings and the Fringe of Physiological State. <i>RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren</i> , 2015, 187, 430-439.	0.7	7
435	How does patients' quality of life guide their preferences regarding aspects of asthma therapy?: a patient-preference study using discrete-choice experiment methodology. <i>Patient</i> , 2008, 1, 309-16.	1.1	7
436	Therapy of bronchial hyper-responsiveness. <i>Clinical and Experimental Allergy</i> , 1991, 21, 379-389.	1.4	6
437	Assessment of agonist- and cell-mediated responses in airway microsections by computerized videomicroscopy. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 1995, 268, L519-L525.	1.3	6
438	COPD: The role of primary care in effective diagnosis, treatment and management. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2003, 12, 16-20.	2.5	6
439	How Does Patients' Quality of Life Guide Their Preferences Regarding Aspects of Asthma Therapy?. <i>Patient</i> , 2008, 1, 309-316.	1.1	6
440	Generation and evaluation of a monoclonal antibody, designated MADL, as a new specific marker for adenocarcinomas of the lung. <i>British Journal of Cancer</i> , 2011, 105, 673-681.	2.9	6
441	Towards a total ban on links with the tobacco industry: new rules for the ERS. <i>European Respiratory Journal</i> , 2012, 40, 809-810.	3.1	6
442	Point: Were Industry-Sponsored Roflumilast Trials Appropriate? Yes. <i>Chest</i> , 2014, 145, 937-939.	0.4	6
443	Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates. <i>Thorax</i> , 2016, 71, 662-663.	2.7	6
444	Rating sputum cell quality in clinical trials for asthma and COPD treatment. <i>International Journal of COPD</i> , 2019, Volume 14, 195-198.	0.9	6
445	Exploration of the sputum methylome and omics deconvolution by quadratic programming in molecular profiling of asthma and COPD: the road to sputum omics 2.0. <i>Respiratory Research</i> , 2020, 21, 274.	1.4	6
446	Allergen extract- and component-based diagnostics in children of the ALLIANCE asthma cohort. <i>Clinical and Experimental Allergy</i> , 2021, 51, 1331-1345.	1.4	6
447	Rounded Mass in the Middle Lobe After Swan-Ganz Catheterization. <i>Chest</i> , 2002, 121, 261-263.	0.4	5
448	Prednisolone response in patients with COPD * Authors' reply. <i>Thorax</i> , 2004, 59, 179-179.	2.7	5
449	EUS: confusion about terminology and its consequences. <i>European Respiratory Journal</i> , 2005, 26, 182-183.	3.1	5
450	Lung Cancer Staging With Minimally Invasive Endoscopic Techniques. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2509.	3.8	5

#	ARTICLE	IF	CITATIONS
451	Treatment of COPD and the TONado trial: a tempest in a teapot?. European Respiratory Journal, 2015, 45, 869-871.	3.1	5
452	Emphysema: Imaging for Endoscopic Lung Volume Reduction. RoFo Fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren, 2015, 187, 543-554.	0.7	5
453	Esophageal ultrasound (EUS) assessment of T4 status in NSCLC patients. Lung Cancer, 2017, 114, 50-55.	0.9	5
454	Influence of body mass on predicted values of static hyperinflation in COPD. International Journal of COPD, 2018, Volume 13, 2551-2555.	0.9	5
455	New Biologics for Severe Asthma: What Patients, What Agents, What Results, at What Cost?. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 406-408.	2.5	5
456	Cytokine levels in children and adults with wheezing and asthma show specific patterns of variability over time. Clinical and Experimental Immunology, 2021, 204, 152-164.	1.1	5
457	Dupilumab efficacy in asthma patients with comorbid chronic rhinosinusitis or nasal polyposis (CRS/NP) in LIBERTY ASTHMA QUEST. , 2018, , .		5
458	The protective effect of low-dose inhaled fenoterol against methacholine and exercise-induced bronchoconstriction in asthma: A dose-response study. Journal of Allergy and Clinical Immunology, 1992, 90, 846-851.	1.5	4
459	Activation of guinea pig eosinophil respiratory burst by leukotriene B ₄ : role of protein kinase C. Fundamental and Clinical Pharmacology, 1992, 6, 353-358.	1.0	4
460	Refractory Eosinophilic Airway Inflammation in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1385-1386.	2.5	4
461	Roflumilast Improves Lung Function and Quality of Life in Chronic Obstructive Pulmonary Disease. Chest, 2004, 126, 709S.	0.4	4
462	Lung cancer patients with small nodes on CT - what's the next step?. Endoscopy, 2006, 38, 77-80.	1.0	4
463	The Effect of Dithiothreitol on the Transcriptome of Induced Sputum Cells. Respiration, 2013, 86, 262-263.	1.2	4
464	Reproducibility of exhaled nitric oxide measurements in overweight and obese adults. BMC Research Notes, 2014, 7, 775.	0.6	4
465	New metrics for translational research. Lancet Respiratory Medicine, the, 2014, 2, e13-e14.	5.2	4
466	Lung cancer staging: a true story. Lancet Respiratory Medicine, the, 2015, 3, 258-259.	5.2	4
467	Roflumilast for asthma: Weighing the evidence. Pulmonary Pharmacology and Therapeutics, 2015, 35, S1-S3.	1.1	4
468	Update in Asthma 2015. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 259-264.	2.5	4

#	ARTICLE	IF	CITATIONS
469	GFF MDI for the improvement of lung function in COPD – A look at the PINNACLE-1 and PINNACLE-2 data and beyond. Expert Review of Clinical Pharmacology, 2017, 10, 685-698.	1.3	4
470	Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?. European Respiratory Journal, 2018, 51, 1702577.	3.1	4
471	Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies. Respiratory Research, 2020, 21, 128.	1.4	4
472	Safety and tolerability of the NE inhibitor BAY 85-8501 in patients with non-CF bronchiectasis. , 2016, , .		4
473	Association of Lung Inflammatory Cells with Small Airways Function and Exhaled Breath Markers in Smokers – Is There a Specific Role for Mast Cells?. PLoS ONE, 2015, 10, e0129426.	1.1	4
474	Relationship between bronchoalveolar lavage neutrophil numbers and lavage fluid elastase and antielastase activities. Lung, 1995, 173, 165-75.	1.4	3
475	Chronic obstructive pulmonary disease (COPD): chronic bronchitis and emphysema. , 2001, , 631-633.		3
476	Isolated airways from current smokers are hyper-responsive to histamine. Clinical and Experimental Allergy, 2001, 31, 1041-1047.	1.4	3
477	On Theophylline, Leukocytes, and Chicken Soup. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 1351-1352.	2.5	3
478	Roflumilast for chronic obstructive pulmonary disease. Lancet, The, 2005, 366, 1845.	6.3	3
479	The effect of dupilumab on lung function parameters in patients with oral corticosteroid-dependent severe asthma. Respiratory Medicine: X, 2020, 2, 100010.	1.4	3
480	<p>Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies</p>. International Journal of COPD, 2020, Volume 15, 99-106.	0.9	3
481	Influence of Cell Quality on Inflammatory Biomarkers in COPD Sputum Supernatant. International Journal of COPD, 2021, Volume 16, 487-493.	0.9	3
482	A randomized trial comparing endosonography followed by surgical staging versus surgical mediastinal staging alone in non-small cell lung cancer: The ASTER study.. Journal of Clinical Oncology, 2010, 28, 7000-7000.	0.8	3
483	Impact of imposed social isolation and use of face masks on asthma course and mental health in pediatric and adult patients with recurrent wheeze and asthma. Allergy, Asthma and Clinical Immunology, 2021, 17, 93.	0.9	3
484	Inhibitory effects of sulfonated shale oil fractions on the oxidative burst and Ca ⁺⁺ mobilization in stimulated macrophages. Arzneimittelforschung, 1994, 44, 166-70.	0.5	3
485	Relationship between prior inhaled corticosteroid use and benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Respiratory Medicine, 2022, 197, 106857.	1.3	3
486	A refugee with a supraclavicular lymph node An uncommon first presentation of carcinoma of the prostate. Netherlands Journal of Medicine, 2001, 58, 22-26.	0.6	2

#	ARTICLE	IF	CITATIONS
487	Bronchodilators: An Overview. , 2001, 31, 54-59.		2
488	Outcome measures in COPD. Primary Care Respiratory Journal: Journal of the General Practice Airways Group, 2004, 13, 177-178.	2.5	2
489	Serving researchers, the impact factor and other conflicts of interest. European Respiratory Journal, 2005, 25, 3-5.	3.1	2
490	Your 10,000 manuscripts. European Respiratory Journal, 2008, 32, 1425-1425.	3.1	2
491	Self-harm on either side of the pond. Lancet, The, 2010, 376, 1224.	6.3	2
492	The Multiple Components of COPD. , 2011, , 1-20.		2
493	BENEFITS OF BUDESONIDE-CONTAINING THERAPIES ON REDUCING LUNG FUNCTION DECLINE IN PATIENTS WITH COPD IN THE ETHOS STUDY. Chest, 2020, 158, A1656-A1659.	0.4	2
494	SAR440340, An Anti-IL-33 Monoclonal Antibody, Demonstrated a Significant Reduction of LOAC Events and Improved Pre-BD FEV1 in Patients with Moderate to Severe Asthma: Results from the Phase 2 Proof of Concept Study. , 2020, , .		2
495	Enhanced neutrophil extracellular trap (NET) formation in sputum of stable COPD patients. , 2015, , .		2
496	Late Breaking Abstract - High-sensitivity troponin I predicts all-cause mortality in stable COPD in the COSYCONET cohort. , 2018, , .		2
497	Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in corticosteroid (CS)-dependent severe asthma patients in LIBERTY ASTHMA VENTURE. , 2018, , .		2
498	Dupilumab Efficacy in Type 2 Inflammatory Asthma: Liberty Asthma QUEST Study. , 2019, , .		2
499	ARIA Update 2008: die allergische Rhinitis und ihr Einfluss auf das Asthma. Allergologie, 2009, 32, 306-319.	0.1	2
500	Allergen-Immuntherapie in der aktuellen COVID-19-Pandemie â€“ ein Positionspapier von ARIA, EAACI, AeDA und DGAKI. Allergologie, 2020, 43, 165-175.	0.1	2
501	Breath volatile organic compound (VOC) patterns in adult asthma patients of the ALLIANCE cohort. , 2019, , .		2
502	Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥ 500 cells/ μ L. European Respiratory Journal, 2022, 59, 2102577.	3.1	2
503	Association of Airway Eosinophilia with Small Airway Dysfunction in Patients with Mild and at Risk for COPD. International Journal of COPD, 0, Volume 17, 1403-1408.	0.9	2
504	Title is missing!. Pharmaceutical Medicine, 2002, 16, 115-127.	0.4	1

#	ARTICLE	IF	CITATIONS
505	âœRefactoryâœEosinophilic Airway Inflammation in Severe Asthma. American Journal of Respiratory and Critical Care Medicine, 2004, 170, 1385-1385.	2.5	1
506	Anti-IgE Treatment Improves Lung Function In Patients With Mild Persistent Allergic Asthma. Journal of Allergy and Clinical Immunology, 2006, 117, S9.	1.5	1
507	Major Adverse Cardiovascular Events In Patients With Chronic Obstructive Pulmonary Disease: Analysis Of 14 Pooled Roflumilast Studies. , 2011, , .		1
508	World Spirometry Day 2012: the highlights so far. Breathe, 2012, 9, 5-8.	0.6	1
509	Response. Chest, 2014, 145, 428.	0.4	1
510	Overweight can be used as a tool to guide case-finding for cardiovascular risk assessment. Family Practice, 2015, 32, 646-651.	0.8	1
511	Seasonal Pattern of COPD Exacerbations in the DYNAGITO Trial. , 2019, , .		1
512	Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Improves Lung Function in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies. , 2019, , .		1
513	Triple Inhaled Therapy in COPD. New England Journal of Medicine, 2020, 383, 1393-1395.	13.9	1
514	Improvements in Lung Function with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Dual Therapies in Patients with COPD: A Sub-Study of the ETHOS Trial. , 2020, , .		1
515	Dupilumab Reduces Oral Corticosteroid Use and Severe Exacerbations and Improves Lung Function in Patients With Oral Corticosteroid-Dependent Severe Asthma With and Without Comorbid Allergic Rhinitis in the Phase 3 LIBERTY ASTHMA VENTURE Study. Journal of Allergy and Clinical Immunology, 2020, 145, AB173.	1.5	1
516	Mediastinum. , 2011, , 115-139.		1
517	Effect of roflumilast on exacerbations in patients with severe COPD and a prior history of hospitalization taking combination therapy. , 2015, , .		1
518	LATE-BREAKING ABSTRACT: PT003, a novel co-suspension MDI glycopyrronium/formoterol fixed-dose combination is superior to monocomponents in patients with COPD. , 2015, , .		1
519	Beneficial effect of the LAMA/LABA glycopyrronium (GP)/formoterol (FF) fixed-dose combination, delivered using a novel MDI co-suspension technology (GFF MDI), in COPD GOLD group A and B patients. , 2016, , .		1
520	KRONOS: 24-week study of triple fixed-dose combination budesonide/glycopyrronium/formoterol (BGF) MDI via co-suspension delivery technology vs glycopyrronium/formoterol (GFF) MDI, budesonide/formoterol (BFF) MDI and BFF inhalation powder in COPD. , 2018, , .		1
521	Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF) Tj ETQq1 1 0.784314 µgBT /Over		1
522	Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial. , 2019, , .		1

#	ARTICLE	IF	CITATIONS
523	Longitudinal data-driven definition of clinical asthma phenotypes in the pediatric arm of the All Age Asthma Cohort (ALLIANCE) of the German Center for Lung Research (DZL). , 2020, , .		1
524	The role of eosinophils in pediatric and adult asthma. , 2020, , .		1
525	Dupilumab shows rapid and sustained suppression of inflammatory biomarkers in asthma patients in LIBERTY ASTHMA QUEST. , 2018, , .		1
526	miR-122-5p and miR-191-5p are increased in plasma small extracellular vesicles in asthma. , 2019, , .		1
527	Exacerbation benefit by blood eosinophil counts with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial: a subgroup analysis. , 2020, , .		1
528	Late Breaking Abstract - Small Airways Dysfunction (SAD) correlates with relevant asthma outcomes: longitudinal results from the Assessment of small Airways involvement In asthma (ATLANTIS) Study. , 2020, , .		1
529	Early-life exposure to tobacco smoke alters airway signaling pathways and later mortality in D. melanogaster. Environmental Pollution, 2022, 309, 119696.	3.7	1
530	Increased LTB4 Metabolites and PGD2 In BAL Fluid after Methacholine Challenge in Asthmatic Subjects. Chest, 1993, 104, A-21.	0.4	0
531	O Manejo Cl�nico da Asma em 1999: Uma Vis�o e a Realidade da Asma na Europa (Estudo AIRE). Revista Portuguesa De Pneumologia, 2001, 7, 169-171.	0.7	0
532	Diagnosing Sarcoidosis by Endoscopic Ultrasound Guided Fine Needle Aspiration (EUS-FNA). Gastrointestinal Endoscopy, 2004, 59, P216.	0.5	0
533	Endoscopic Ultrasound in Non-Small Cell Lung Cancer and its Impact on Surgical Staging. Gastrointestinal Endoscopy, 2005, 61, AB269.	0.5	0
534	P-347 Endoscopic ultrasound and the assessment of tumour invasion (T4). Lung Cancer, 2005, 49, S207.	0.9	0
535	Transesophageal Ultrasound and the Assessment of Tumour Invasion in Non-Small Cell Lung Cancer. Gastrointestinal Endoscopy, 2006, 63, AB259.	0.5	0
536	Mannose binding lectin (MBL) levels predict lung function decline in severe asthma. European Respiratory Review, 2006, 15, 224-225.	3.0	0
537	Role of purinergic receptors in the activation of human airway smooth muscle cells by the antimicrobial peptide LL-37. European Respiratory Review, 2006, 15, 182-184.	3.0	0
538	Implementation of EUS-FNA for Lung Cancer Staging. Gastrointestinal Endoscopy, 2007, 65, AB119.	0.5	0
539	COPD: more than respiratory � Authors' reply. Lancet, The, 2008, 371, 28.	6.3	0
540	A Unique Spirometric Phenotype in COPD. American Journal of Respiratory and Critical Care Medicine, 2008, 178, 432-433.	2.5	0

#	ARTICLE	IF	CITATIONS
541	Elastic Fiber Density in Large and Small Airways and Parenchyma in Lungs of Non-Smokers, Smokers and COPD Patients.. , 2009, , .		0
542	EUS-FNA for Mediastinal Restaging of Non Small Cell Lung Carcinoma (NSCLC). Gastrointestinal Endoscopy, 2009, 69, AB336.	0.5	0
543	Is Asthma Control Test (ACT) the Best Measure To Quantify Asthma Control in Severe Not Controlled Patients?.. , 2009, , .		0
544	Forced Expiratory Volume In One Second % Predicted Is Associated With Abnormal Aerobic Capacity In Patients With Limited And Diffuse Systemic Sclerosis. , 2010, , .		0
545	Reproducibility Of Exhaled NO Measurements In Overweight Subjects. , 2010, , .		0
546	Lumican And Biglycan Expression In Lungs Of COPD Patients. , 2010, , .		0
547	Is There A Good Tool To Measure Asthma Control On Severe Asthma Patients ?. , 2010, , .		0
548	Brazilian Severe Asthma Characterization And Its Phenotypes. , 2010, , .		0
549	Increased Lung-to-finger Circulation Time In obstructive Sleep Apnea. , 2010, , .		0
550	S35 A randomised controlled trial comparing combined EBUS/EUS followed by surgical staging versus surgical staging alone in non-small cell lung cancer: the ASTER study. Thorax, 2010, 65, A18-A18.	2.7	0
551	Tiotropium Reduces Exacerbations Versus Salmeterol Irrespective Of Baseline ICS Treatment In The Poet-COPD; Study. , 2011, , .		0
552	Seasonal Distribution Of Exacerbations In The Poet-COPD; Study. , 2011, , .		0
553	Anti-inflammatory Effects Of Budesonide In Human Lung Fibroblasts Are Independent Of HDAC2. , 2011, , .		0
554	Glycoproteins In Large And Small Airways And In Lung Parenchyma Of COPD Patients. , 2011, , .		0
555	Cigarette Smoke Extract Affects Release Of IL-8 And SLPI In Differentiated Primary Bronchial Epithelial Cell Cultures (PBEC) From COPD Versus Controls. , 2011, , .		0
556	Inhaled Long-Acting β_2 -Agonists Versus Anticholinergics in Older Patients With Chronic Obstructive Pulmonary Disease. Annals of Internal Medicine, 2011, 155, 561.	2.0	0
557	Identification Of Single Nucleotide Polymorphisms In MicroRNA 146A. , 2011, , .		0
558	EUS and EBUS in Non-“Small Cell Lung Cancer. , 2011, , 45-58.		0

#	ARTICLE	IF	CITATIONS
559	The race for healthy lungs starts with spirometry testing. <i>Breathe</i> , 2012, 8, 273-275.	0.6	0
560	Prof. Andrzej Szczeklik, 1938â€“2012: aspirin-induced asthma and much more: Figure 1â€“. <i>European Respiratory Journal</i> , 2012, 39, 1283-1286.	3.1	0
561	Avoiding backward steps in COPD: looking again at roflumilast. <i>European Respiratory Journal</i> , 2012, 39, 225-226.	3.1	0
562	Generation Of IPS-Like Cells From COPD Lung Fibroblasts. , 2012, , .		0
563	A Interdisciplinary Lung Transplant Center: A Collaboration Between a University Hospital and a Transregional Center for Pulmonology. <i>Transplantation</i> , 2012, 94, 935.	0.5	0
564	Antiinflammatory Drugs. , 2012, , 213-220.		0
565	Rebuttal From Drs Suissa and Rabe. <i>Chest</i> , 2014, 145, 942-943.	0.4	0
566	Elastic Recoil Revisited. <i>Chest</i> , 2015, 148, 297-298.	0.4	0
567	P294â€“Benefits of tiotropium/olodaterol over tiotropium at delaying clinically significant events in patients with copd classified as gold B. <i>Thorax</i> , 2016, 71, A251.3-A252.	2.7	0
568	Treatment of First Exacerbation Predicts Future Risk of Exacerbations in Patients with COPD in the DYNAGITO Trial. , 2019, , .		0
569	COPD EXACERBATION RATE BY BASELINE COPD ASSESSMENT TEST SCORE IN THE DYNAGITO STUDY. <i>Chest</i> , 2019, 156, A1758-A1759.	0.4	0
570	Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma. , 2019, , .		0
571	The Fevipiprant Phase IIIb Systemic Corticosteroid Avoidance Study: SHIELD. , 2019, , .		0
572	Dupilumab Improved Asthma Control and Health-Related Quality of Life in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study. , 2019, , .		0
573	Dupilumab Reduces Severe Exacerbations and Improves Lung Function Regardless of Baseline Bronchodilator Reversibility in Patients with Uncontrolled Moderate-to-Severe Asthma Enrolled in the LIBERTY ASTHMA QUEST Study. , 2019, , .		0
574	Dupilumab Improved Lung Function in Patients with Uncontrolled, Moderate-to-Severe Asthma Despite Exacerbation Events During the LIBERTY ASTHMA QUEST Study. , 2019, , .		0
575	Dupilumab Improved Morning and Evening Daily Asthma Symptoms in Patients with Oral-Corticosteroid-Dependent Severe Asthma in the Phase 3 LIBERTY ASTHMA VENTURE Study. , 2019, , .		0
576	12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-Suspension Delivery Technology in Patients with COPD. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
577	The Frequency of Exacerbations Treated with Antibiotics, Steroids or Both Differs by GOLD Stage in Patients with COPD in the DYNAGITO Trial. , 2019, , .		0
578	Benefits of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) on Symptoms and Quality of Life in Patients with Chronic Obstructive Pulmonary Disease (COPD) in the ETHOS Trial. , 2020, , .		0
579	DUPILUMAB IMPROVES LUNG FUNCTION IN PATIENTS IRRESPECTIVE OF ON-STUDY ASTHMA EXACERBATIONS. Chest, 2020, 158, A1729-A1733.	0.4	0
580	Single-Inhaler Triple Combination Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) at Two Corticosteroid Dose Levels in COPD: ETHOS Trial. , 2020, , .		0
581	COL4A3 Degradation Is Increased in Severe, Type 2 Exacerbating Asthmatics. , 2020, , .		0
582	COL4A3 Degradation Predicts Anti-IgE Treatment Response in Severe Asthma. , 2020, , .		0
583	Dupilumab Efficacy in GINA-Defined Difficult-to-Treat Type 2 Asthma Patients. Journal of Allergy and Clinical Immunology, 2020, 145, AB19.	1.5	0
584	Benefits of Tiotropium/Olodaterol Over Tiotropium Alone in Delaying Clinically Significant Deterioration in Patients with COPD. , 2020, , .		0
585	Implementation of transesophageal ultrasound (EUS-FNA) for lung cancer staging. Journal of Clinical Oncology, 2008, 26, 7605-7605.	0.8	0
586	Lung Function and Bronchial Challenge Testing for the Allergist. , 2009, , 101-126.		0
587	Extrapulmonary effects of COPD. , 2013, , 300-303.		0
588	Leukotrienes in induced airway obstruction. , 1998, , 73-77.		0
589	Versican and collagen-III expression in bronchial and pulmonary muscular arteries in COPD patients. , 2015, , .		0
590	The role of sustained physical inactivity in the progression of exercise intolerance and muscle depletion in COPD. , 2015, , .		0
591	Tolerability of different dosing regimens of roflumilast in severe COPD (OPTIMIZE). , 2016, , .		0
592	Physical activity in patients with asthma. , 2016, , .		0
593	Long-acting bronchodilators (LABDs) and major adverse cardiac events (MACE) in patients with COPD: A pooled analysis of 12 randomised trials. , 2016, , .		0
594	International perspectives on severe asthma: Current and future challenges in patient care. , 2016, , .		0

#	ARTICLE	IF	CITATIONS
595	Neutrophils in bronchial mucosa, sputum and blood after administration of the CXCR2-antagonist AZD5069 - An explorative study in neutrophilic asthma. , 2016, , .		0
596	Association of angiotensin-like protein 4 with cardiovascular function in patients with COPD. , 2016, , .		0
597	Molecular phenotyping of chronic bronchitis: mucin and inflammatory gene expression heterogeneity in COPD. , 2017, , .		0
598	Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD. , 2017, , .		0
599	Physical activity in patients with sarcoidosis. , 2017, , .		0
600	Beitrag der Zytologie zur Diagnostik von Thymustumoren. Atemwegs- Und Lungenkrankheiten, 2018, 44, 383-389.	0.0	0
601	Influences of obstruction and hyperinflation on electrocardiographic P wave, QRS and T wave axis in COPD. , 2018, , .		0
602	Influence of body mass on predicted values of static hyperinflation in COPD. , 2018, , .		0
603	Extrapulmonary effects of COPD. , 2019, , 339-343.		0
604	Pneumonia risk with budesonide-containing therapies in COPD: pooled analysis of three Phase III studies. , 2019, , .		0
605	Regional analysis of COPD exacerbation rates in the DYNAGITO trial. , 2019, , .		0
606	Analysis of exacerbation rates by time interval post-randomization in the KRONOS Phase III study of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI). , 2019, , .		0
607	Late Breaking Abstract - Blood eosinophil count and exacerbation history in COPD: pooled analysis of 24,103 patients. , 2019, , .		0
608	S29â€¦The impact of GOLD stage on the effectiveness of tiotropium/olodaterol in preventing COPD exacerbations in the DYNAGITO trial. , 2019, , .		0
609	S102â€¦Eosinophil counts as a predictor of future COPD exacerbations in the DYNAGITO trial. , 2019, , .		0
610	Beitrag der intraoperativen Zytologie zur Schnell-Diagnostik thoraxchirurgisch gewonnener Proben. Pneumologie, 2020, 74, .	0.1	0
611	12-Hour Lung Function Assessment of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Delivered by Co-suspension Delivery Technology in Patients with COPD. , 2020, 74, .		0
612	Iron deficiency and lung function decline in stable COPD â€œ a prospective cohort study. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
613	Small airway evolution of a Brazilian severe asthmatic cohort (BRASASP): 10 years follow up. , 2020, , .		0
614	AsthmaphÄnotypen in der ALL Age Asthma Kohorte â€žALLIANCEâ€œ des DZL â€œ Aktuellder Stand, Ergebnisse, Ausblick. Pneumologie, 2020, 74, .	0.1	0
615	Seasonal Variation in COPD Exacerbations: a Post-Hoc Analysis from the KRONOS Phase III Study of Budesonide/Glycopyrrolate/Formoterol Metered Dose Inhaler (BGF MDI). Pneumologie, 2020, 74, .	0.1	0
616	COPD exacerbation rates by month in the ETHOS trial with budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels. , 2020, , .		0
617	Predictive modelling of COPD exacerbation rates using baseline risk factors. , 2020, , .		0
618	Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS. , 2020, , .		0
619	Seasonal variation in COPD exacerbation rates: budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) at two ICS dose levels in the ETHOS trial. , 2020, , .		0
620	The pro-resolving lipid mediator lipoxin A4 inversely correlates with proinflammatory chemokines and identifies a subgroup of asthma patients with disease progression. , 2020, , .		0
621	Effect of dupilumab on severe exacerbations and lung function in patients with baseline blood eosinophils =500 cells/ÄµL. , 2020, , .		0
622	Malignes Mesotheliom: Vor- und Nachteile der zytologischen Untersuchung von ErgÄ¼ssen. Atemwegs- Und Lungenkrankheiten, 2020, 46, 651-657.	0.0	0